Phase II study of concomitant fluorouracil, hydroxyurea, cetuximab and hyperfractionated intensity modulated radiation therapy for locally advanced head and neck cancer

Trial Profile

Phase II study of concomitant fluorouracil, hydroxyurea, cetuximab and hyperfractionated intensity modulated radiation therapy for locally advanced head and neck cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2010

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil (Primary) ; Hydroxycarbamide (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 12 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top